Literature DB >> 8017334

Fuel and energy metabolism in fasting humans.

M G Carlson1, W L Snead, P J Campbell.   

Abstract

Fuel and energy homeostasis was examined in six male volunteers during a 60-h fast by using a combination of isotopic tracer techniques ([3-3H]glucose, [2H5]glycerol, [1-14C]palmitate, and L-[1-13C]leucine) and indirect calorimetry. Plasma glucose concentration and hepatic glucose production decreased by 30% with fasting (5.2 +/- 0.1 to 3.8 +/- 0.2 mmol/L and 11.8 +/- 0.5 to 8.2 +/- 0.6 mumol.kg-1.min-1, respectively, both P < 0.001) and glucose oxidation declined approximately 85% (P < 0.01). Lipolysis and primary (intraadipocyte) free fatty acid (FFA) reesterification increased 2.5-fold (1.7 +/- 0.2 to 4.2 +/- 0.2 mumol.kg-1.min-1 and 1.5 +/- 0.4 to 4.2 +/- 0.8 mumol.kg-1.min-1, respectively, both P < 0.05). This provided substrate for the increase in fat oxidation (from 2.7 +/- 0.3 to 4.3 +/- 0.1 mumol.kg-1.min-1, P < 0.01), which contributed approximately 75% of resting energy requirements after the 60-h fast and increased the supply of glycerol for gluconeogenesis. Proteolysis and protein oxidation increased approximately 50% during fasting (P < 0.01 and P < 0.05, respectively). We conclude that the increase in FFA reesterification with fasting modulates FFA availability for oxidation and maximizes release of glycerol from triglyceride for gluconeogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8017334     DOI: 10.1093/ajcn/60.1.29

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  14 in total

1.  Computational model of in vivo human energy metabolism during semistarvation and refeeding.

Authors:  Kevin D Hall
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-01-31       Impact factor: 4.310

2.  Sequential muscle biopsies during a 6-h tracer infusion do not affect human mixed muscle protein synthesis and muscle phenylalanine kinetics.

Authors:  Elena Volpi; David L Chinkes; Blake B Rasmussen
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-08-19       Impact factor: 4.310

3.  The Role of Leptin in Maintaining Plasma Glucose During Starvation.

Authors:  Rachel J Perry; Gerald I Shulman
Journal:  Postdoc J       Date:  2018-03

4.  Effect of BMI and fat mass on HIV disease progression in HIV-infected, antiretroviral treatment-naïve adults in Botswana.

Authors:  S S Martinez; A Campa; H Bussmann; S Moyo; J Makhema; F G Huffman; O D Williams; M Essex; R Marlink; M K Baum
Journal:  Br J Nutr       Date:  2016-04-18       Impact factor: 3.718

Review 5.  Aquaglyceroporins: implications in adipose biology and obesity.

Authors:  Ana Madeira; Teresa F Moura; Graça Soveral
Journal:  Cell Mol Life Sci       Date:  2014-10-31       Impact factor: 9.261

6.  Increased lipolysis in LCHAD deficiency.

Authors:  M U Halldin; A Forslund; U von Döbeln; C Eklund; J Gustafsson
Journal:  J Inherit Metab Dis       Date:  2006-12-09       Impact factor: 4.982

7.  Predicting metabolic adaptation, body weight change, and energy intake in humans.

Authors:  Kevin D Hall
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-24       Impact factor: 4.310

8.  Lipolysis and fatty acid metabolism in men and women during the postexercise recovery period.

Authors:  Gregory C Henderson; Jill A Fattor; Michael A Horning; Nastaran Faghihnia; Matthew L Johnson; Tamara L Mau; Mona Luke-Zeitoun; George A Brooks
Journal:  J Physiol       Date:  2007-09-13       Impact factor: 5.182

9.  A Muscle-Centric Perspective on Intermittent Fasting: A Suboptimal Dietary Strategy for Supporting Muscle Protein Remodeling and Muscle Mass?

Authors:  Eric Williamson; Daniel R Moore
Journal:  Front Nutr       Date:  2021-06-09

10.  Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.

Authors:  Takashi Sasaki; Yutaka Seino; Atsushi Fukatsu; Soichi Sakai; Yoshishige Samukawa
Journal:  Adv Ther       Date:  2014-02-18       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.